On December 9, 2021 HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, reported that it will deliver a virtual presentation on the clinical applications of our odetiglucan (Imprime PGG) therapy for patients with metastatic and late-stage cancer at the ESMO (Free ESMO Whitepaper) Immuno-Oncology Virtual Congress 2021, December 8-11, 2021 (Press release, HiberCell, DEC 9, 2021, View Source;utm_medium=rss&utm_campaign=hibercell-to-present-clinical-applications-of-odetiglucan-and-the-role-of-beta-glucan-in-cancer-treatment-at-esmo-immuno-oncology-virtual-congress-2021 [SID1234596646]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This 20-minute presentation will focus on the broad applicability of odetigulcan in combination with different therapeutic agents and across multiple cancers.
Title: Beta-glucan in cancer treatment
Presenter: Nandita Bose, Ph.D., Senior Vice President of Clinical and Translational Medicine, HiberCell
Session: Trained Immunity Educational Session
Time/Date: Saturday, December 11, 2021: 10:00 – 10:20 am CT
Odetiglucan is a Dectin-1, pattern recognition receptor agonist that is currently in a phase 2 clinical trial in combination with pembrolizumab, an anti-programmed death receptor-1 (PD-1) used in cancer immunotherapy, for the treatment of metastatic, hormone-refractory breast cancer patients. The World Health Organization assigned "odetiglucan" as the International Nonproprietary Name (INN) for Imprime PGG as of November 2021.
For more information about HiberCell’s clinical trials, visit the website at www.HiberCell.com.